XLO — Xilio Development Inc
NASDAQ · Healthcare · Biotechnology
$9.14
+$0.26 (+2.95%)
Xilio Development Inc (XLO) is a biotechnology company listed on NASDAQ. It is led by Rene Russo BCPS, Pharm.D., based in 828 Winter Street, Waltham, MA, United States, 02451, with about 76 employees. Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Latest reported XLO revenue for 2025-09-30 was $19.1M. Net income was -$45.4M. Revenue was up 135.8% from 2025-06-30 to 2025-09-30. XLO currently screens at market cap $55.3M.
Use this XLO page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the XLO quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the XLO SEC filings page. Lician reads the product cache first so this HTML stays unique to Xilio Development Inc even when a live quote feed is slow.
About Xilio Development Inc
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
XLO Key Statistics
Market Cap
$55.32M
Volume
5,400
Previous Close
$9.19
Day Range
$9.10 – $9.22
P/B Ratio
0.75
EPS
-$1.09
Revenue
$6.34M
Net Income
-$58.24M
Gross Profit
$0.00
Free Cash Flow
$0.00
Profit Margin
-918.0%
Employees
76
XLO Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $6.34M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$58.24M | -$76.40M | -$88.22M | -$75.80M |
| EPS (Diluted) | -$1.09 | -$2.78 | -$3.22 | -$13.52 |
Total Assets
$71.08M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$55.29M
Operating Cash Flow
-$18.38M
Free Cash Flow
$0.00
Xilio Development Inc Company Information
- President, CEO & Director
- Rene Russo BCPS, Pharm.D.
- Headquarters
- 828 Winter Street, Waltham, MA, United States, 02451
- Website
- xiliotx.com
- Phone
- 857 524 2466
- IPO / Founded
- 2021-10-22
- Sector
- Healthcare
- Industry
- Biotechnology